HemCon Medical Technologies Selects Blood Bank Computer Systems, for Tracking and Monitoring Internal Systems

Auburn, Wash. Dec. 15, 2008 -- HemCon Medical Technologies Inc. has selected the BBCS Primary 5.0 Application, from Blood Bank Computer Systems Inc., to support their automated Blood Establishment Computer System (B.E.C.S) needs while they await FDA approval for a new, unique lyophilized plasma-based resuscitation program.

“The BBCS Primary Application was the obvious choice for this project”, states Dr. Clint Pepper, VP Product and Process Development of HemCon Medical Technologies. “The BBCS Primary Application has the flexibility to adapt to our unique information needs while still maintaining the integrity of a FDA 510(k) approved product.”

In May 2008, the U.S. Army selected HemCon Medical Technologies Inc. as the sole source to develop, test and secure FDA approval for a lyophilized (freeze-dried), human plasma (LHP) product and delivery system. The $15.4 million, multi-year cooperative agreement will support the research and development of the new process. The project is expected to be complete in 2010.

Blood Bank Computer Systems was awarded FDA 510(k) clearance for their BBCS Primary Application in December 2004. The Primary Application is a robust system that has been acclaimed as a powerful enterprise wide solution for the blood banking and transfusion industry.

“We are excited with the opportunity to be a part of this innovative project that will support the men and women of the Armed Forces with safe, life-saving plasma” adds Beth Simon, President/CEO of Blood Bank Computer Systems Inc. “It will be a great opportunity to demonstrate the flexibility of the BBCS Primary Application while meeting the needs and requirements of a new diverse part of the industry.”

About Blood Bank Computer Systems Inc.
Privately owned and headquartered in the Pacific Northwest, Blood Bank Computer Systems Inc., (BBCS, Inc.), has been one of the blood banking industry’s complete software solutions for information and risk management since 1987. BBCS, Inc. is committed to developing and providing safe and effective software solutions, which provide management with the tools necessary to minimize the risks associated with operating a blood center and a cross match lab. BBCS, Inc. works closely with their dynamic client group and business partners to continually improve the product line and provided services. To learn more about BBCS, Inc. please visit www.bbcsinc.com.

About HemCon Medical Technologies Inc.
HemCon Medical Technologies Inc. is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including Lyophilized Human Plasma and NanospiderTM technologies. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland; England; Germany and the Czech Republic. For more information, please visit www.hemcon.com.